MedTrace Logo

Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient

NCT03360123 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2018-06-19

No results posted yet for this study

Summary

This study will evaluate the perceptions of the effects of two anxiolytic medications commonly used during dental treatment in patients weighing 40 kilograms or more.

Conditions

  • Dental Anxiety

Interventions

DRUG

Midazolam Hydrochloride 2Mg/mL Syrup

Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.

DRUG

Triazolam 0.125 MG

Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Whitney Eichholz, DDS · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2018-04-11
Completion
2018-04-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03360123 on ClinicalTrials.gov